Real-Time Access
at the Point of Diagnosis

Aperture analyzes diagnostic data captured through Concentriq, Proscia’s enterprise pathology platform, which powers a global network of digitized laboratories. It links to other testing and longitudinal records via tokenization to incorporate relevant clinical context and draws from a mix of structured and unstructured sources – including whole slide images, AI-enriched tissue, AI-derived biomarkers, molecular results, and genomic data.

Once your lab has adopted digital pathology with Concentriq, you’ll automatically gain access to the opportunities that Aperture delivers. Contact us today to learn about unlocking value with Concentriq and Aperture.

Unlike EHR- or genomics-dependent platforms, Aperture identifies eligible patients within moments of pathology diagnosis — days to weeks earlier than competing approaches. Aperture’s patient profiles are comprehensive and built on unique data, unlocking rare or emerging cohorts critical to targeted therapy trials and strategies but invisible to conventional patient identification and surveillance methods. And because Concentriq sits at the heart of the diagnostic workflow, any additional testing or workup required can be executed by our diagnostic laboratory network.

Yes. Drawing from a global diagnostic network processing 32,000+ daily diagnoses, Aperture provides the scale needed to identify even the smallest, hard-to-find patient populations. The AI interface enables sponsors to define complex inclusion and exclusion criteria through structured queries, delivering precise cohort matching.

AI models on Concentriq power biomarker detection, image feature extraction, and diagnostic metadata analysis. These results, including quantified tissue morphology, visual phenotypes detection, and feature extraction for trial matching and real-world evidence, are all able to be queried on Concentriq. In addition, Aperture leverages AI to rapidly sift through tissue images, biomarkers, molecular results, and clinical records to match patients with the right trials and treatments, while also powering evidence for regulatory filings, diagnostic development, label expansions, and payer discussions.

Aperture sources data from a geographically and demographically diverse patient population from all care settings. This diversity in data helps sponsors improve trial representation, meet regulatory expectations, and design studies that better reflect real-world patient populations.

Aperture analyzes diagnostic and clinical data captured at the point of diagnosis to match patients against complex trial inclusion and exclusion criteria. This includes information derived directly from digitized slides and lab systems, as well as integrated clinical context from sources like EHRs and genomics. By drawing from structured and unstructured sources, Aperture provides a more complete view of each patient’s diagnostic profile — enabling precise, real-time trial matching.

Yes. Aperture’s AI-enriched diagnostic data and biomarker monitoring insights can be used to generate regulatory-grade real-world evidence. Sponsors use this data to strengthen FDA and EMA submissions, support label expansions, inform payer negotiations, and accelerate market access for precision therapies. This data is delivered via Concentriq — the same enterprise platform that supports 16 of the top 20 pharmaceutical companies across discovery, development, and commercialization.

Aperture is available today for select Proscia Concentriq® customers. If you’re interested in early access or want to learn more about how Aperture can support your organization, please contact us at rwd@proscia.com.